Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
AssigneeTurnstone Biologics Corp.
InventorsSebastien Delpeut, David Stojdl
Life of this patent
Estimating the term…
Abstract
Various embodiments of the invention provide recombinant oncolytic viruses engineered to express human cytomegalovirus (HCMV) glycoprotein UL40 and/or Kaposi's sarcoma associated herpesvirus (KSHV) K5 protein, and methods and uses of the same for treating cancer. Also provided are combination therapies involving a T lymphocyte infiltrating (TIL) cell therapy and a provided recombinant oncolytic virus for treating a cancer, including solid tumors.
Claims48
A nucleic acid comprising a recombinant Orthopoxvirus genome and one or more transgenes comprising (a) a nucleotide sequence encoding UL40 and/or (b) a nucleotide sequence encoding K5.
Dependencies are inferred from the claim text.